Hymenolepis nana

Other Tapeworms of Medical Importance

Hymenolepis nana (Siebold 1852)

  • Pronunciation: \hī-mə-ˈnäl-ə-pəs\na-nə

Introduction

  • Species Overview:

    • Hymenolepis nana (
      HI-men-OL-eh-pis\ Na-nuh) is a small tapeworm in the order Cyclophyllidea.

    • Distribution: Found worldwide, predominantly infecting children.

    • Prevalence: High prevalence rates observed in certain regions, with infection rates in children reaching up to 25%.

    • Common Settings: Particularly common in impoverished neighborhoods and institutional environments.

  • Morphology:

    • Length: 34–45 mm.

    • Body Structure: Comprises 150–200 proglottids attached loosely to the intestinal lumen.

    • Scolex: Features four suckers and a single row of hooks.

  • Reservoir Hosts: Rodents are significant reservoirs for this tapeworm.

  • Life Cycle:

    • H. nana completes its life cycle exclusively within human hosts, akin to Strongyloides stercoralis.

    • Autoinfection may lead to high worm burdens, especially in immunosuppressed patients.

  • Clinical Cases:

    • Notable case: In 2015, malignant transformation and metastasis of H. nana cells documented in an individual with HIV-1.

    • Related species: H. microstoma, identified as a secondary infection in patients with H. nana from remote communities in Western Australia.

Historical Information

  • Discovery:

    • 1852: Theodore Bilharz first identified H. nana during an autopsy of a boy who had died from meningitis, revealing adult parasites in his small intestine.

    • 1887: Giovanni Grassi demonstrated H. nana’s direct transmission cycle in rats.

    • 1911: Nicolle and Minchin showed an indirect transmission cycle involving fleas or beetles.

    • 1921: Y. Saeki established that H. nana could also have a direct transmission cycle in humans.

Life Cycle

  • Transmission: Infection can originate from:

    • Ingesting cysticercoid metacestodes through infected insects.

    • Ingesting embryonated eggs directly.

  • Infective Stages: Found in Tenebrio larvae (mealworms) and rat feces.

  • Hatching Process:

    • Upon ingestion, eggs hatch in the small intestine, and oncospheres penetrate the lamina propria of the intestinal villi.

    • Larvae differentiate into cysticercoid stage, attach to the villous tissue, and mature into immature adults.

  • Growth:

    • Maturation occurs within 3 to 4 weeks if eggs are ingested and within 2 weeks if the cysticercoid is ingested.

    • Lifespan of adult worms is approximately 4–6 weeks; however, autoinfection can lead to prolonged infections lasting years.

Cellular and Molecular Pathogenesis

  • Symptoms and Immune Response:

    • Infections are typically self-limited in adults but can be more severe in young children.

    • Cysticercoids are non-immunogenic, allowing autoinfection, while egg ingestion sparks strong immune responses.

    • Eosinophils are attracted to infections by the cysticercoid which may help prevent new infections.

    • INF-γ and IgE antibodies are significant in the immune response against H. nana.

Clinical Disease

  • Symptoms: Most infections are asymptomatic, yet heavy infections can lead to:

    • Diarrhea

    • Potentially abdominal pain, headache, and anal itching, although these may be related to co-infections.

Diagnosis

  • Methodology: Definitive diagnosis via microscopic identification of embryonated eggs in stool. Whole segments of strobila can also be identified or eggs expressed from gravid proglottids.

Treatment

  • Drug of Choice: Praziquantel is effective against both cysticercoid and adult worms; a dosage of 5–10 mg/kg is recommended.

  • Alternative Treatment: Niclosamide targets adults but is ineffective against metacestodes. Repeated treatment may be necessary if only niclosamide is used.

  • Other Options: Nitazoxanide has been explored as a broad-spectrum antiparasitic for children.

Prevention and Control

  • Best Practices: Preventing food and water contamination and controlling rodent populations are key strategies. Achieving a cure in individuals, especially children, may be difficult due to autoinfection. Reinfection is common in endemic locations.

Hymenolepis diminuta (Rudolphi 1819)

  • Pronunciation: \hī-mə-ˈnäl-ə-pəs\də-minü-tə

Introduction

  • Species Overview:

    • Hymenolepis diminuta (
      HI-men-OL-oh-pis\ di-min-oo-tuh) is a tapeworm prevalent worldwide, infecting primarily children.

    • Reservoir hosts include dogs, cats, and various rodents.

Historical Information

  • Discovery:

    • 1819: Described by Karl Asmund Rudolphi.

    • 1858: David Weinland noted its infection in humans.

Life Cycle

  • Transmission:

    • Ingestion of cysticercoids through infected insects.

    • Immature worms attach to the intestinal wall and mature in 18 days, reaching lengths of 50 cm with approximately 1,000 proglottids.

  • Lifecycle Completion: Requires ingestion by an appropriate intermediate host like fleas or flour beetles; the eggs of H. diminuta are not infectious for humans.

Clinical Disease

  • Symptoms: Usually asymptomatic, but heavier infections may result in:

    • Abdominal pain

    • Anorexia

    • Irritability.

Diagnosis

  • Methodology: Identification of eggs in stool is the definitive diagnostic method, with possibilities of detecting whole worm segments or extracting eggs from segments.

Treatment

  • Drug of Choice:

    • Praziquantel is recommended for treatment.

    • Niclosamide is an acceptable alternative if administered over several days.

  • Laboratory Model: H. diminuta serves as a model for in vivo testing of anti-cestode therapies in laboratory settings.

Prevention and Control

  • Control Efforts: Similar to H. nana, controlling H. diminuta requires addressing infections in both humans and reservoir hosts, with a focus on preventing food contamination by insect hosts but is challenging in less developed regions.

Dipylidium caninum (Linnaeus 1758)

  • Pronunciation: \dī-ˌpī-ˈlid-ē-əm\kā-nin-əm

Introduction

  • Species Overview: Dipylidium caninum (
    DYE-pie-LID-ee-um\ KAY-nin-um) primarily inhabits the small intestine of dogs, cats, and occasionally humans, with a Greek nomenclature that translates to "double pore"
    based on its morphology.

Life Cycle

  • Transmission: Acquired through ingesting an infected adult flea (typically Ctenocephalides canis or Ctenocephalides felis).

  • Lifecycle Phases:

    • Cysticercoid is liberated within the host's digestive tract and adheres to the intestinal surface.

    • Adult worms release gravid proglottids within 25 days, which break down to release eggs that exit via feces.

    • Infective cycle can transfer through flea larvae ingesting eggs.

Clinical Disease

  • Symptoms:

    • Generally lacks identifiable clinical symptoms, but some reports suggest mild abdominal pain, diarrhea, and irritability particularly in children under 8 years old.

Diagnosis

  • Methodology: Diagnosis is confirmed through microscopic identification of the characteristic egg clusters in stool or directly identifying proglottids if available.

Treatment

  • Drug of Choice: Praziquantel or niclosamide are recommended for effective treatment.

Prevention and Control

  • Control Measures: Eliminating fleas in domestic pets and treating infected animals significantly reduces the potential for human infection.